Calithera Biosciences Inc. (NASDAQ:CALA) shares rose 2.8% during mid-day trading on Wednesday . The company traded as high as $3.35 and last traded at $3.35, with a volume of 63,691 shares trading hands. The stock had previously closed at $3.26.

CALA has been the subject of a number of recent analyst reports. JMP Securities restated a “buy” rating on shares of Calithera Biosciences in a research note on Wednesday, June 8th. Zacks Investment Research downgraded Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, May 17th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Calithera Biosciences in a research note on Thursday, May 12th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $10.38.

The stock’s market capitalization is $61.59 million. The firm has a 50-day moving average of $3.25 and a 200-day moving average of $4.73.

Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Tuesday, August 9th. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. Analysts forecast that Calithera Biosciences Inc. will post ($2.16) earnings per share for the current fiscal year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.